# US 2007/0087986 A1 · Compositions and methods for enhancing immunity by chemoattractant adjuvants

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2007/0087986 A1
- Document ID: US20070087986A1
- Status: Published application
- Kind: A1
- Application number: 11/496,267
- Filed: 2006-07-31
- Published: 2007-04-19
- Earliest claimed: 2004-01-26
- Inventors: Brett Premack; Matthew Walters; Thomas Schall
- Web page: https://patentgrep.com/patent/US20070087986A1

## CPC

- A61K 39/07: Bacillus
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 2039/543: {intranasal}
- A61K 2039/55516: {Proteins; Peptides}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- C12N 2710/00088: for redistribution
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention is directed to methods and compositions for enhancing immunity, including mucosal immunity. The compositions include an antigen or immunogen, a ligand for a Toll-like receptor and at least one chemoattractant.

## Claims

### Claim 1

An immunogenic composition, comprising:
an antigen or immunogen;
at least one chemoattractant; and
a ligand for a Toll-like receptor (TLR).

### Claim 2 (depends on 1)

The immunogenic composition of claim 1, wherein the ligand for TLR is a TLR9 ligand.

### Claim 3 (depends on 2)

The immunogenic composition of claim 2, wherein the TLR9 ligand is CpG oligonucleotide.

### Claim 4 (depends on 1)

The immunogenic composition of claim 1, wherein the chemoattractant is a chemokine or a w-peptide.

### Claim 5 (depends on 4)

The immunogenic composition of claim 4, wherein the chemokine is selected from the group consisting of IL-8, GCP-2, Gro α, Gro β, Gro γ, ENA-78, PBP, MIG, IP-10, I-TAC, SDF-1α (PBSF), BLC (BCA-1), MIP-1α, MIP-1β, RANTES, HCC-1, -2, -3, and 4, MCP-1, -2, -3, and -4, eotaxin-1, eotaxin-2, TARC, MDC, MIP-3α (LARC), MIP-3β (ELC), 6Ckine (LC), I309, TECK, lymphotactin, fractalkine (neurotactin), TCA-4, Exodus-2, Exodus-3, and CKβ-11.

### Claim 6 (depends on 4)

The immunogenic composition of claim 4, wherein the ligand for TLR is a TLR9 ligand.

### Claim 7 (depends on 1)

The immunogenic composition of claim 1, wherein the chemoattractant is a SHAAGtide polypeptide having at least 80% sequence identity to SEQ ID NO: 1.

### Claim 8 (depends on 7)

The immunogenic composition of claim 7, wherein the ligand for TLR is a TLR9 ligand.

### Claim 9 (depends on 1)

The immunogenic composition of claim 1, wherein the chemoattractant is a SHAAGtide polypeptide selected from the group consisting of SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11.

### Claim 10 (depends on 4)

The immunogenic composition of claim 4, wherein the w-peptide is selected from the group consisting of SEQ ID NOS: 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, and 58.

### Claim 11 (depends on 1)

The immunogenic composition of claim 1, wherein the immunogenic composition is a vaccine composition.

### Claim 12 (depends on 1)

The immunogenic composition of claim 1, wherein the antigen is a viral protein, polypeptide, or a fragment thereof; a cancer or tumor antigen; infectious disease agent; a bacterial agent; a parasite agent; or a fungal agent.

### Claim 13 (depends on 1)

The immunogenic composition of claim 1, wherein the composition induces mucosal immunity in a subject.

### Claim 14 (depends on 13)

The immunogenic composition of claim 13, wherein the subject is a mammal.

### Claim 15 (depends on 13)

The immunogenic composition of claim 13, wherein the subject is a human.

### Claim 16 (depends on 1)

The immunogenic composition of claim 1, wherein the composition enhances an antibody response in a subject.

### Claim 17 (depends on 1)

The immunogenic composition of claim 1, wherein the composition is for treatment of an infectious disease.

### Claim 18 (depends on 1)

The immunogenic composition of claim 1, wherein the composition is for treatment of a cancer.

### Claim 19

A method of enhancing immunity, comprising delivering to a subject an effective amount of a composition comprising an antigen, at least one chemoattractant, and a ligand for a Toll Like Receptor (TLR).

### Claim 20 (depends on 19)

The method of claim 19, wherein the ligand for TLR is a TLR9 ligand.

### Claim 21 (depends on 19)

The method of claim 19, wherein the method enhances mucosal immunity.

### Claim 22 (depends on 19)

The method of claim 19, further comprising a step of measuring a level of immune response to the immunogenic composition, wherein the immune response is directed to the antigen or immunogen.

### Claim 23 (depends on 22)

The method of claim 22, wherein the step of measuring comprises determining humoral response.

### Claim 24 (depends on 22)

The method of claim 22, wherein the step of measuring comprises determining cell-mediated immune response.

### Claim 25

A method for identifying an adjuvant compound that enhances immunity to an antigen or immunogen, comprising
delivering an immunogenic composition comprising the antigen or immunogen, at least one chemoattractant and a ligand for a Toll-like receptor to a subject; and
measuring a level of immune response to the immunogenic composition, wherein the immune response is directed to the antigen or immunogen.

### Claim 26

A method of inducing a mucosal immunity, comprising applying to a mucosal membrane in a subject an effective amount of a composition comprising an antigen or immunogen, at least one chemoattractant, and a CpG.

### Claim 27 (depends on 26)

The method of claim 26, wherein the mucosal membrane is vaginal.

### Claim 28 (depends on 26)

The method of claim 26, wherein the mucosal membrane is nasal.
